New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 7, 2014
09:10 EDTQCOR, AGIO, PFE, MNKD, AEO, MAT, P, VOCS, MNK, WWEOn The Fly: Pre-market Movers
HIGHER: Questcor (QCOR), up 27% after agreeing to be bought by Mallinckrodt (MNK) for cash, stock valued at $86.10 per Questcor share... Agios Pharmaceuticals (AGIO), up 25% after program shows "promising clinical activity" for advanced blood cancers, shares upgraded at JPMorgan... Vocus (VOCS), up 47% after agreeing to be acquired by GTCR for $446.5M, or $18.00 per share... Pandora (P), up 1.3% following upgrade at Wedbush. LOWER: MannKind (MNKD), down 13% after announcing FDA extension of PDUFA date for Afrezza... American Eagle (AEO), down 2.2% following downgrade at Cowen... Pfizer (PFE), down 2.8% after announcing data for palbociclib in metastatic breast cancer... Mattel (MAT), down 3% following downgrade at BMO Capital... WWE (WWE), down 1.2% after cautious mention in Barron's, company announcing WrestleMania 30 grossed $10.9M.
News For QCOR;MNK;VOCS;P;MAT;AEO;MNKD;PFE;AGIO;WWE From The Last 14 Days
Check below for free stories on QCOR;MNK;VOCS;P;MAT;AEO;MNKD;PFE;AGIO;WWE the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
July 16, 2014
16:09 EDTMNKMallinckrodt initiated with an Outperform at Oppenheimer
Target $100.
14:55 EDTMATMattel July 39 straddle priced for 5.1% move into Q2
Subscribe for More Information
11:53 EDTMNKDStocks with call strike movement; MNKD SUNE
MannKind (MNKD) January 17 call option implied volatility increased 6% to 79, SunEdison (SUNE) October 28 call option implied volatility increased 3% to 58 according to IVolatility.
11:50 EDTMATMattel technical comments before earnings
Subscribe for More Information
10:36 EDTPFETreasury calls on Congress to halt inversion deals
Subscribe for More Information
10:35 EDTQCOROptions with decreasing implied volatility
Subscribe for More Information
09:27 EDTPFEPfizer to acquire InnoPharma for upfront cash payment of $225M
Subscribe for More Information
07:59 EDTPFETreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
07:04 EDTPFEPfizer says primary endpoint met in Phase 3 study of BeneFIX
Pfizer announced the positive results of a Phase 3 study comparing a prophylaxis regimen of BeneFIX Coagulation Factor IX 100 IU/kg once-weekly to on-demand treatment in people with moderately severe to severe hemophilia B. The top-line results of the study showed that the primary study endpoint was met and hemophilia B patients taking once-weekly BeneFIX showed a statistically significant reduction in the annualized bleeding rate relative to on-demand treatment with BeneFIX. In the study, the median ABR value, a commonly used measure of efficacy for prophylaxis regimens in hemophilia, was 2.0 for the prophylaxis regimen, compared to 33.6 for the on-demand regimen, representing a 94% decrease in bleeding rates. The mean ABR value was 3.6 for the prophylaxis period, compared to 32.9 for the on-demand treatment, which represents a reduction of 89%. Study results also showed that prophylaxis treatment significantly reduced both spontaneous and traumatic ABR compared to on-demand treatment with BeneFIX. In addition to meeting the primary endpoint, the secondary study endpoints showed that none of the 1,254 prophylaxis infusions administered during the study were associated with a less than expected therapeutic effect occurrence, which was defined as a spontaneous bleed occurring within 48 hours of a prophylaxis infusion. These results are preliminary, top-line data and are subject to additional analyses. Complete results from this study will be submitted for presentation at upcoming medical congresses and submitted for publication in a peer-reviewed journal.
July 15, 2014
10:13 EDTPPandora calls active on renewed takeover chatter
Pandora July 25.5 and 28 calls are active on total call volume of 6,800 contracts (400 puts) on renewed takeover chatter. July call option implied volatility is at 64, August is at 67, September is at 61; compared to its 26-week average of 55 according to Track Data. Active call volume suggests traders taking positions for upside price movement.
10:04 EDTPPandora spikes higher, testing resistance
The shares have spiked higher in the last five minutes off the low of the day, currently at $26.71. Traders may push to test resistance at yesterday's high at $27.19. Support is at $26.40, the prior session low.
09:58 EDTPRumor: Pandora moves up on renewed takeover chatter
06:30 EDTPDOJ investigating music publishing, possible price coordination, WSJ reports
Subscribe for More Information
July 14, 2014
15:09 EDTMNK, QCORQuestcor rises after S-4 effective, interest from other suitors disclosed
Subscribe for More Information
07:04 EDTMNK, QCORMallinckrodt and Questcor update transaction
Mallinckrodt (MNK) and Questcor (QCOR) announced that the registration statement on Form S-4 filed with the SEC by Mallinckrodt on May 16 and amended on July 11 which includes a joint proxy statement of Mallinckrodt and Questcor that also constitutes a prospectus of Mallinckrodt, was declared effective on July 11. The companies have also each scheduled shareholder meetings on August 14 for shareholders of record on July 9 to consider (i) in the case of Mallinckrodt, its proposal to issue its ordinary shares in connection with its proposed acquisition of Questcor and (ii) in the case of Questcor, approval of the merger agreement with Mallinckrodt and related matters. The transaction is currently expected to be completed in August.
July 11, 2014
11:33 EDTMNKDStocks with call strike movement; MNKD SUNE
Subscribe for More Information
09:09 EDTQCOROn The Fly: Pre-market Movers
Subscribe for More Information
07:25 EDTMATMattel July volatility elevated into Q2 and outlook
Mattel July call option implied volatility is at 40, August is at 23, October is at 20; compared to its 26-week average of 22 according to Track Data, suggesting large near term price movement into the expected release of Q2 results on July 17.
06:39 EDTMNK, QCORQuestcor reports Acthar adverse effects data, NY Times says
The number of patients who reported an adverse effect last year while taking Questcor's (QCOR) Acthar drug amounted to almost 5% of prescriptions dispensed, the company stated in a regulatory filing released yesterday, according to The New York Times. The filing marked the first time that the company has disclosed any difficulties experienced by Acthar patients, the newspaper added. Questcor has agreed to be bought by Mallinckrodt (MNK). Reference Link
06:10 EDTPJPMorgan expects solid Q2 results in Internet space
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use